JP7224916B2 - 真菌感染の処置のための投薬レジメン - Google Patents

真菌感染の処置のための投薬レジメン Download PDF

Info

Publication number
JP7224916B2
JP7224916B2 JP2018548363A JP2018548363A JP7224916B2 JP 7224916 B2 JP7224916 B2 JP 7224916B2 JP 2018548363 A JP2018548363 A JP 2018548363A JP 2018548363 A JP2018548363 A JP 2018548363A JP 7224916 B2 JP7224916 B2 JP 7224916B2
Authority
JP
Japan
Prior art keywords
salt
resistant
subject
dose
neutral form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018548363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511496A (ja
JP2019511496A5 (enExample
Inventor
バーティザル，ケネス
ダルワラ，ポール
ロッケ，ジェフリー，ブライアン
オング，ブーン
サンディソン，テイラー
タイ，ダーク
Original Assignee
シダラ セラピューティクス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シダラ セラピューティクス インコーポレーテッド filed Critical シダラ セラピューティクス インコーポレーテッド
Publication of JP2019511496A publication Critical patent/JP2019511496A/ja
Publication of JP2019511496A5 publication Critical patent/JP2019511496A5/ja
Priority to JP2022125186A priority Critical patent/JP7322259B2/ja
Application granted granted Critical
Publication of JP7224916B2 publication Critical patent/JP7224916B2/ja
Priority to JP2023121182A priority patent/JP2023139211A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018548363A 2016-03-16 2017-03-15 真菌感染の処置のための投薬レジメン Active JP7224916B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022125186A JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン
JP2023121182A JP2023139211A (ja) 2016-03-16 2023-07-26 真菌感染の処置のための投薬レジメン

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662309211P 2016-03-16 2016-03-16
US62/309,211 2016-03-16
US201662350591P 2016-06-15 2016-06-15
US62/350,591 2016-06-15
US201662415928P 2016-11-01 2016-11-01
US62/415,928 2016-11-01
US201662418727P 2016-11-07 2016-11-07
US62/418,727 2016-11-07
US201662419076P 2016-11-08 2016-11-08
US62/419,076 2016-11-08
US201662436716P 2016-12-20 2016-12-20
US62/436,716 2016-12-20
PCT/US2017/022551 WO2017161016A1 (en) 2016-03-16 2017-03-15 Dosing regimens for treatment of fungal infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022125186A Division JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン

Publications (3)

Publication Number Publication Date
JP2019511496A JP2019511496A (ja) 2019-04-25
JP2019511496A5 JP2019511496A5 (enExample) 2020-05-07
JP7224916B2 true JP7224916B2 (ja) 2023-02-20

Family

ID=59850952

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018548363A Active JP7224916B2 (ja) 2016-03-16 2017-03-15 真菌感染の処置のための投薬レジメン
JP2022125186A Active JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン
JP2023121182A Pending JP2023139211A (ja) 2016-03-16 2023-07-26 真菌感染の処置のための投薬レジメン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022125186A Active JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン
JP2023121182A Pending JP2023139211A (ja) 2016-03-16 2023-07-26 真菌感染の処置のための投薬レジメン

Country Status (8)

Country Link
US (2) US11712459B2 (enExample)
EP (2) EP3430400B1 (enExample)
JP (3) JP7224916B2 (enExample)
CN (1) CN109154603A (enExample)
CA (1) CA3017485A1 (enExample)
ES (1) ES2955711T3 (enExample)
MA (1) MA43825A (enExample)
WO (1) WO2017161016A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036778T2 (hu) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Gombaellenes szerek és alkalmazásuk
EP2827710B1 (en) 2012-03-19 2019-11-20 Cidara Therapeutics, Inc. Dosing regimens for echinocandin class compounds
WO2017120471A1 (en) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CA3069423C (en) 2017-07-12 2025-04-15 Cidara Therapeutics Inc Formulations for the treatment of fungal infections
WO2019241626A1 (en) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent
US12060439B2 (en) 2018-10-25 2024-08-13 Napp Pharmaceutical Group Limited Polymorph of echinocandin antifungal agent
WO2020232037A1 (en) * 2019-05-16 2020-11-19 Scynexis, Inc. Antifungal agents, like ibrexafungerp for candida auris decolonization

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512392A (ja) 2012-03-19 2015-04-27 シダラ セラピューティクス インコーポレーテッド エキノキャンディン系化合物のための投与レジメン

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
EP0697879A4 (en) 1993-05-04 1998-01-14 Merck & Co Inc AMINOALKYL ETHER DERIVATIVES OF CYCLOHEXAPEPTIDES
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
CA2211138A1 (en) 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
AR006598A1 (es) 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
USRE38984E1 (en) 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
AU766091B2 (en) 1998-12-09 2003-10-09 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1582204T3 (da) 1999-03-03 2013-11-04 Lilly Co Eli Echinocandin-farmaceutiske formuleringer, der indeholder miceldannende overfladeaktive stoffer
IL145188A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Processes for making pharmaceutical oral ecb formulations and compositions
US6309622B1 (en) * 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
EP1172105A4 (en) * 1999-04-16 2002-09-04 Fujisawa Pharmaceutical Co ANTIFUNGAL COMPOSITIONS
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
EP1576150A4 (en) 2002-10-16 2006-05-03 Univ Texas METHOD AND COMPOSITIONS TO SAVE THE EFFECTIVENESS OF BIOLOGICALLY ACTIVE INGREDIENTS
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
EP1654036B1 (en) 2003-07-22 2007-12-26 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP1907588B1 (en) 2005-07-26 2013-06-05 The University of Medicine and Dentistry of New Jersey Assays for resistance to echinocandin-class drugs
US20070231258A1 (en) 2006-03-31 2007-10-04 Karyon Ctt Ltd. Peptide conjugates
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
US10568859B2 (en) 2009-02-25 2020-02-25 Mayne Pharma Llc Topical foam composition
WO2010128096A1 (en) 2009-05-07 2010-11-11 Dsm Ip Assets B.V. Method for the preparation of cyclopeptides
EP2470168B1 (en) 2009-08-26 2018-01-31 BioElectron Technology Corporation Methods for the prevention and treatment of cerebral ischemia
EP2470190A4 (en) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc ECHINOCANDINDERIVATE
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
HUE036778T2 (hu) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Gombaellenes szerek és alkalmazásuk
EP2739652B1 (en) 2011-08-04 2017-04-05 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (en) 2013-01-18 2014-07-24 University Of Utah Research Foundation Modified release osmotic pump for ph-responsive intravaginal drug delivery
WO2014124504A1 (en) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms
US9919055B2 (en) 2013-03-15 2018-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Sugar-linker-drug conjugates
CN112656782A (zh) 2013-05-01 2021-04-16 尼奥酷里私人有限公司 治疗细菌感染的方法
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
US20180256673A1 (en) 2015-09-16 2018-09-13 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2017049105A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
WO2017120471A1 (en) 2016-01-08 2017-07-13 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN110290797A (zh) 2016-11-01 2019-09-27 奇达拉治疗公司 用于预防和治疗真菌感染的单剂量方法
US20210002346A1 (en) 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
WO2018144600A1 (en) 2017-01-31 2018-08-09 Cidara Therapeutics, Inc. Methods for treating fungal infections
WO2018187574A1 (en) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2018191692A1 (en) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Methods for treating fungal infections
CA3069423C (en) 2017-07-12 2025-04-15 Cidara Therapeutics Inc Formulations for the treatment of fungal infections
US20200164023A1 (en) 2017-08-03 2020-05-28 Cidara Therapeutics, Inc. Methods for preventing and treating intra-abdominal candidiasis
WO2019241626A1 (en) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512392A (ja) 2012-03-19 2015-04-27 シダラ セラピューティクス インコーポレーテッド エキノキャンディン系化合物のための投与レジメン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chatterjee, S. et al.，Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris，BMC Genomics，2015年，Vol. 16，686
Lee, W.G. et al.，First three reported cases nosocomial fungemia caused by Candida auris，Journal of Clinical Microbiology，2011年09月，Vol. 49, No. 9，pp. 3139-3142
安原 眞人 ほか，基礎から学ぶ臨床薬物動態 臨床薬物動態の基礎知識，臨床薬理，2010年，第41巻，第4号，p.155-158

Also Published As

Publication number Publication date
JP7322259B2 (ja) 2023-08-07
WO2017161016A1 (en) 2017-09-21
MA43825A (fr) 2021-04-07
ES2955711T3 (es) 2023-12-05
JP2019511496A (ja) 2019-04-25
CN109154603A (zh) 2019-01-04
CA3017485A1 (en) 2017-09-21
EP4268896A3 (en) 2024-01-03
EP3430400A1 (en) 2019-01-23
EP3430400A4 (en) 2019-10-30
JP2022169599A (ja) 2022-11-09
US11712459B2 (en) 2023-08-01
EP4268896A2 (en) 2023-11-01
EP3430400B1 (en) 2023-06-21
US20240108684A1 (en) 2024-04-04
US20190216885A1 (en) 2019-07-18
JP2023139211A (ja) 2023-10-03

Similar Documents

Publication Publication Date Title
JP7322259B2 (ja) 真菌感染の処置のための投薬レジメン
Hata et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
Seyedmousavi et al. Systemic antifungal agents: current status and projected future developments
Chang et al. New developments and directions in the clinical application of the echinocandins
US20180256673A1 (en) Methods for treating fungal infections
WO2018102407A1 (en) Methods for preventing fungal infections
EP3534927A1 (en) Single dose methods for preventing and treating fungal infections
AU2024227501A1 (en) Antifungal agents with enhanced activity in acidic pH
JP2023030113A (ja) 併用される抗真菌剤
Spencer et al. Systemic fungal infections: A pharmacist/researcher perspective
WO2000041688A1 (en) Use of an amiodarone compound as antifungal agent
HK40103014A (en) Dosing regimens for treatment of fungal infections
US20220273610A1 (en) Antimycotic
HK1261465A1 (en) Dosing regimens for treatment of fungal infections
HK40003635A (en) Dosing regimens for treatment of fungal infections
HK40003635B (en) Dosing regimens for treatment of fungal infections
Kasanah et al. SPK-843 Aparts/Kaken
WO2025120231A1 (en) Antifungal compounds
Siles Identification of novel antifungal activity in Prestwick Chemical Library against Candida albicans biofilms
Chan Pharmacokinetics of voriconazole in horses and alpacas
EA047299B1 (ru) Фармацевтическая комбинация тритерпеноидного производного энфумафунгина с изавуконазолом и ее применение для лечения инвазивного аспергиллеза легких
MX2007014485A (es) Medicamento a base de saponina sc-2 para el tratamiento de candidiasis.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181218

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20200305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7224916

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350